Entact Bio is a startup based in the United States, most recent round Series A, 1 tracked investor.
Entact Bio is a company founded in 2018 headquartered in the United States. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Entact Bio is developing precision medicines that enhance the function of beneficial proteins using a proprietary platform called Encompass™ to create enhancement-targeting chimeric (ENTAC™) molecules, aiming to treat diseases by restoring cellular health through improved protein function.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.